Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: The results of the KKESH international collaborative retina study group

Igor Kozak, Ahmad Mansour, Rocio I. Diaz, Jorge I. Calzada, Francesco Pichi, Vanessa Cruz-Villegas, Manuel Diaz-Llopis, Jay Chhablani, Mauricio Martinez-Cartier, Martin Meerhoff, William F. Mieler, J. Fernando Arevalo, Eman Al Kahtani, Nicola Ghazi, Sawsan Nowilaty, Saba Al Rashaed, Hassan A. Al-Dhibi, Yahya A. Al-Zahrani, Vishali Gupta, Sultan Ahmad Al-KahtaniNaif Abdullah Al-Marzoog, Abdullah Saad Al-Robaie, Sulaiman Al-Sulaiman, Abdulelah Al-Abdullah, Ahmad Al-Bar, Yousef Al-Dhafiri, Abdullah Al-Qahtani, Khalid Al-Rubaie, Saeed Al-Shahrani, Maha Al-Shehri, Muhammad Younis, Wilson Heriot, Anthony Hall, Friederike Mackensen, Focke Ziemssen, Emilie Mercé, Rajiv Anand, Hamid Ahmadieh, Jorge Mataix, Paolo Nucci, David Sarraf, Gian Paolo Giuliari, Thomas A. Albini

Research output: Contribution to journalArticle

Abstract

PURPOSE:: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. METHODS:: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). RESULTS:: There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse). CONCLUSION:: Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.

Original languageEnglish
Pages (from-to)2044-2052
Number of pages9
JournalRetina
Volume34
Issue number10
DOIs
Publication statusPublished - Oct 12 2014

    Fingerprint

Keywords

  • antiangiogenic therapy
  • children
  • choroidal neovascularization

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Kozak, I., Mansour, A., Diaz, R. I., Calzada, J. I., Pichi, F., Cruz-Villegas, V., Diaz-Llopis, M., Chhablani, J., Martinez-Cartier, M., Meerhoff, M., Mieler, W. F., Arevalo, J. F., Al Kahtani, E., Ghazi, N., Nowilaty, S., Al Rashaed, S., Al-Dhibi, H. A., Al-Zahrani, Y. A., Gupta, V., ... Albini, T. A. (2014). Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: The results of the KKESH international collaborative retina study group. Retina, 34(10), 2044-2052. https://doi.org/10.1097/IAE.0000000000000200